These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30459339)

  • 1. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B.
    Zhao K; Liu S; Chen Y; Yao Y; Zhou M; Yuan Y; Wang Y; Pei R; Chen J; Hu X; Zhou Y; Zhao H; Lu M; Wu C; Chen X
    Emerg Microbes Infect; 2018 Nov; 7(1):186. PubMed ID: 30459339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression.
    Tsukuda S; Watashi K; Iwamoto M; Suzuki R; Aizaki H; Okada M; Sugiyama M; Kojima S; Tanaka Y; Mizokami M; Li J; Tong S; Wakita T
    J Biol Chem; 2015 Feb; 290(9):5673-84. PubMed ID: 25550158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors.
    Goh B; Choi J; Kang JA; Park SG; Seo J; Kim TY
    J Pharm Biomed Anal; 2020 Jan; 178():112959. PubMed ID: 31722821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F; Fardel O; Gripon P
    Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTCP Oligomerization Occurs Downstream of the NTCP-EGFR Interaction during Hepatitis B Virus Internalization.
    Fukano K; Oshima M; Tsukuda S; Aizaki H; Ohki M; Park SY; Wakita T; Wakae K; Watashi K; Muramatsu M
    J Virol; 2021 Nov; 95(24):e0093821. PubMed ID: 34613794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.
    Okuyama-Dobashi K; Kasai H; Tanaka T; Yamashita A; Yasumoto J; Chen W; Okamoto T; Maekawa S; Watashi K; Wakita T; Ryo A; Suzuki T; Matsuura Y; Enomoto N; Moriishi K
    Sci Rep; 2015 Nov; 5():17047. PubMed ID: 26592202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection.
    Yan Y; Allweiss L; Yang D; Kang J; Wang J; Qian X; Zhang T; Liu H; Wang L; Liu S; Sui J; Chen X; Dandri M; Zhao J; Lu F
    Emerg Microbes Infect; 2019; 8(1):879-894. PubMed ID: 31179847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
    Nio Y; Akahori Y; Okamura H; Watashi K; Wakita T; Hijikata M
    Biochem Biophys Res Commun; 2018 Jun; 501(3):820-825. PubMed ID: 29723527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an
    Tu T; Budzinska MA; Vondran FWR; Shackel NA; Urban S
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29437961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ; Hu W; Zhang TY; Mao YY; Liu NN; Wang SQ
    Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication.
    Qiao L; Sui J; Luo G
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
    Lempp FA; Wiedtke E; Qu B; Roques P; Chemin I; Vondran FWR; Le Grand R; Grimm D; Urban S
    Hepatology; 2017 Sep; 66(3):703-716. PubMed ID: 28195359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.